USFDA Closes Inspection of Zydus Lifesciences Office in New Jersey with NIL Observations
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The USFDA conducted an onsite inspection of the pharmacovigilance and post marketing surveillance system at the office of Zydus Lifesciences in New Jersey, USA. The inspection took place from September 22 to September 25, 2026. The review closed with NIL observations.
From equitybulls.com
Why it matters
The successful inspection outcome suggests compliance with US regulatory standards for the company's operations. On the day of the announcement, shares of Cadila Healthcare Limited were trading up, closing at Rs. 1202.00 in BSE.
From equitybulls.com
Who's involved
- New JerseyState of New Jersey where the company's office is located.
Keep exploring
The entities involved
-
New Jersey
state of the United States of America
Related events
- Ocean Power Technologies is based in Monroe Township, New Jersey.
- Conduent's headquarters are located in Florham Park, New Jersey.
- NJEDA drives investment in the life sciences sector in New Jersey.
- Johnson & Johnson started its roots in New Jersey.
- Companies with heavy corporate footprints in New Jersey are facing scrutiny regarding alleged market monopolies and corporate trends affecting local residents.